MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX)*
Organization & Developments: Syndax
Parents
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX)*
Children
*Development and commercialization of novel cancer therapies
*Syndax aims to combine the drug with other cancer drugs to treat tumors that haven’t responded to other therapies.
*The drug, entinostat, is in Phase 2 clinical testing, and acts against certain enzymes that influence specific epigenetic alterations that drive cancer growth and drug tolerance.
2011: Epigenetics startup revealed three sets of data on its lung cancer drug at the Study of Lung Cancer conference (2011)
2018: Syndax is hit with a setback during the ASCO preview round as lead drug flops in mid-stage study – Endpoints News
2018: Syndax Pharmaceuticals Is In For A Potentially Transformative 2018 - Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)
2020: Syndax_Why This Bullishly Ranked Biotech Stock Just Broke Out To A Record High
2021: Syndax Pharmaceuticals: Updated Analysis After Reporting Interim Phase 1 Data_ seekingalpha.com
2022: Syndax Pharmaceuticals (SNDX) Presents at 64th ASH Annual Meeting & Exposition_seekingalpha.com
2022: Syndax Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation_seekingalpha.com
2023: Sizing Up Syndax Pharmaceuticals_ seekingalpha.com
2023: Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023
2024: FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks
2024: Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
2024: Syndax Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Syndax Pharmaceuticals: Navigating Through A Pivotal Year_seekingalpha.com
2024: Syndax Pharmaceuticals: One Down And One To Go
2024: Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
2024: Syndax scores FDA approval for Revuforj after it disappointed in another acute leukemia indication
2025: Syndax Looks Tantalizing, But Looks Can Be Deceptive_seekingalpha.com
2025: Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals
2025: Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges
Jumps
*Key People: Syndax
Finance & Acquisitions: Syndax